Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 999-1000, 2007; 10.1373/clinchem.2007.086579
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCaddon, A.
Right arrow Articles by Hudson, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCaddon, A.
Right arrow Articles by Hudson, P. R.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2007;53:999-1000.)
© 2007 American Association for Clinical Chemistry, Inc.

Editorials

Methylation and Phosphorylation: A Tangled Relationship?

Andrew McCaddon1,a,1 and Peter R. Hudson2,2

1 Cardiff School of Medicine, Wrexham, United Kingdom
2 Department of Medicinal Biochemistry, Maelor Hospital, Wrexham, United Kingdom

aAddress correspondence to this author at: Cardiff School of Medicine, Gardden Road Surgery, Rhosllanerchrugog, Wrexham LL14 2EN, United Kingdom. Fax +44-1978-845782; e-mail andrew.mccaddon@pearlmedical.co.uk.

The first 20% of the full text of this article appears below.

Many neurodegenerative diseases are associated with distinctive brain lesions. One particular group of heterogeneous dementias and movement disorders is characterized by intracellular accumulations of abnormal filaments called neurofibrillary tangles (NFT), formed by the microtubule-associated protein tau. These neurodegenerative tauopathies include Pick disease and Alzheimer disease (AD), but the term also encompasses a range of other clinical conditions that share a common end-point: neurodegeneration with pathological tau accumulation (1).

Tau occurs predominantly in neuronal axons, where it binds to microtubules and regulates their length and "treadmilling" dynamics. Tight regulation of microtubule activity is critical to cell viability, and fine regulation of tau is likely to be equally important (2).

Tau activity is modulated by phosphorylation, and the ability of tau to bind to and stabilize microtubules correlates inversely with its degree of phosphorylation. This relationship has led to the suggestion of a role for tau in the adaptive response of neurons to stress (3). Tau phosphorylation may represent a physiological and reversible process integral to the stress response system. For example, in animal models, tau phosphorylation occurs in response to ether anesthesia, cold-water stress, and starvation (4).

Tau is highly phosphorylated in several neurodegenerative diseases associated with NFT formation. Disordered phosphorylation disrupts the normal colocalization of tau with microtubules, leading to further phosphorylation at fibrillogenic sites and/or cleavage by caspases. This process increases the probability of tau-tau interactions leading . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.